|
|
465-M.
 | The Impact of Baseline CD4 T-Cell Count and Adherence on Rates of Disease Progression among HIV-Infected Patients Initiating Triple Drug Therapy
E. Wood*, R. Hogg, B. Yip, K. Craib, M. O'Shaughnessy, and J. Montaner
BC Ctr. for Excellence in HIV/AIDS and Univ. of British Columbia, Vancouver, Canada
|
466-M.
| Viral Dynamics and Their Relationships with Baseline Factors and Virologic Responses in Naïve HIV-1-Infected Patients Receiving Abacavir in Combination with Selected HIV-1 Protease Inhibitors
H. Wu*1, 3, J. Mellors2, D. McMahon2, P. Ruan3, L. Dix4, W. Spreen4, D. Kelleher4, and M. Lederman5
1Frontier Sci. and Technology Res. Fndn., Chestnut Hill, MA; 2Univ. of Pittsburgh Sch. of Med., PA; 3Harvard Sch. of Publ. Hlth., Boston, MA; 4GlaxoSmithKline, Res. Triangle Park, NC; and 5Case Western Reserve Univ., and Univ. Hosp., Cleveland, OH
|
467-M.
| Initiating Potent Combination Antiretroviral Therapy within 1 Year of the First Clinic Visit for Patients at All CD4 Cell Count Levels Is Associated with Better Long-Term Outcomes
M. Kitahata*, P. Dillingham, and S. Van Rompaey
Univ. of Washington, Seattle
|
468-M.
| Impact of Initial CD4 Cell Response to Highly Active Antiretroviral Therapy (HAART) on Subsequent CD4 T-Cell Trends
S. B. Shade*, P. Hunt, J. N. Martin, S. G. Deeks, and D. I. Abrams
Univ. of California, San Francisco
|
| 469-M. | When to Initiate Highly Active Antiretroviral Therapy (HAART): HIV Disease Progression According to CD4+ Level at Initiation of Therapy among Persons with Durable Virologic Suppression
T. R. Sterling*, R. E. Chaisson, J. Keruly, and R. Moore
Johns Hopkins Univ., Baltimore, MD
|
470-M.
| Impact of Baseline CD4 Cell Count and Viral Load on Durability of Virologic Response through 96 Weeks for Lopinavir/Ritonavir (LPV/r) and Nelfinavir (NFV) in a Phase III Clinical Trial
M. King*, B. Bernstein, P. Cernohous, J. Moseley, E. Bauer, and E. Sun
Abbott Labs., Abbott Park, IL.
|
471-M.
| Viral Replication and Long-Term Clinical Progression in Patients Treated with Potent Antiretroviral Therapy
M. Egger*1, B. Ledergerber2, P. Grob2, L. Perrin3, P. Burgisser4, P. Erb5, W. Fierz6, J-C. Piffaretti7, M. Gorgievski8, and R. Weber2 for the Swiss HIV Cohort Study (SHCS)
1Univ. of Bristol, UK; Univ. of 2Zurich, 3Geneva, 4Lausanne, 5Basel and 8Berne, Switzerland; and Microbiology Inst. of 6St.Gall and 7Lugano, Switzerland
|
472-M.
| Greater Impact of HAART on Survival in People Age 50 and Older with HIV Infection Compared to Younger People in an Urban Observational Cohort
J. L. Perez* and R. D. Moore
Johns Hopkins Univ., Baltimore, MD
|
